Interaction Of Group A Streptococci With Intracellular Innate Immune Defence
Funder
National Health and Medical Research Council
Funding Amount
$824,252.00
Summary
The pathogenic bacterium group A streptococcus (GAS) is estimated to cause ~700 million cases of self-limited throat or skin infection each year worldwide. GAS infections result in over 600,000 human deaths. This disease burden places GAS in the “top 10” causes of human infectious disease deaths worldwide. We have discovered a hitherto unknown mechanism by which GAS subvert the human immune system. An improved understanding of this mechanism will lead to novel ways to combat GAS infections.
Worldwide Molecular Analysis Of Streptococcus Pyogenes Scarlet Fever Outbreaks
Funder
National Health and Medical Research Council
Funding Amount
$544,041.00
Summary
The microorganism group A Streptococcus (also called GAS or Streptococcus pyogenes) ranks among the top 10 infectious disease killers of humans. Recently, outbreaks of scarlet fever have occurred in both Asia and the United Kingdom, placing a serious strain on health systems. The reasons underlying these outbreaks remain unknown. Our team will lead the global effort to characterise this rise in scarlet fever, and provide recommendations and solutions to health professionals.
Public Health Interventions For The Control Of Group A Streptococcal Disease And Scabies In Endemic Populations
Funder
National Health and Medical Research Council
Funding Amount
$470,144.00
Summary
The bacterium Group A Streptococcus (GAS) is an important cause of morbidity and mortality globally. The skin infestation scabies is an important portal of entry for GAS because it predisposes to skin sores. I propose to develop two research programs aimed at controlling these diseases: one is development of GAS vaccines and the other is investigating population-based interventions for control of scabies and related GAS skin infection.
Scarlet Fever Pandemic And Reversing Antibiotic Resistance
Funder
National Health and Medical Research Council
Funding Amount
$3,414,215.00
Summary
(1) Scarlet fever is a disease caused by the bacterial pathogen group A Streptococcus (GAS) that has abruptly re-emerged (>600,000 cases since 2011). To contain this outbreak, my team will develop a scarlet fever vaccine. (2) My team has discovered a class of safe compounds that break antibiotic resistance, restoring antibiotic efficacy. We will now translate this exciting and unparalleled discovery into the clinic for the treatment of antibiotic resistant superbugs.
The Efficacy Of Mass Drug Administration Strategies To Control Scabies In A Highly Endemic Population.
Funder
National Health and Medical Research Council
Funding Amount
$705,396.00
Summary
Globally there are an estimated 300 million scabies cases annually. Many Pacific countries, including Fiji, have among the highest rates in the world. This island based study in Fiji will compare the short and long term efficacy of two mass treatment protocols using oral ivermectin or topical permethrin against conventional treatment. This study will be the first population-wide treatment trial for scabies that compares new interventions to standard of care treatment.
Tropical Diseases: Translating Discoveries Into Better Health
Funder
National Health and Medical Research Council
Funding Amount
$19,803,660.00
Summary
Major progress being made in control of many infectious diseases occurring in tropical areas, including malaria worms and the bacteria that causes strep throat. However, currently available tools will not permit their full control or elimination. This program is aimed to improve understanding of these diseases and to develop the much needed tools that will be required for their elimination.
Activation And Inhibition Of The Plasminogen/Plasmin System
Funder
National Health and Medical Research Council
Funding Amount
$800,663.00
Summary
Plasmin is crucial enzyme present in blood plasma that functions in clot dissolution, inflammation, tissue remodeling, and wound healing. We aim to study how this enzyme system is controlled, by studying its interaction with receptors, co-factors and inhibitors. The information we gain will help drive the development of new generation therapeutics for the fine control of plasmin function in clotting disease, bleeding and inflammation.
Preclinical Studies Of Group A Streptococcal Vaccine Candidates
Funder
National Health and Medical Research Council
Funding Amount
$532,492.00
Summary
Group A streptococcus causes 520,000 deaths each year. A safe and effective vaccine is not commercially available. We have identified 2 new protective candidate antigens, and we seek to undertake critical preclinical studies to provide further proof-of-concept data. This work will underpin commercial decisions by our industry partner (Wyeth) leading to human trials and the development of a safe group A streptococcal vaccine for human use.
Optimising Intervention Strategies To Reduce The Burden Of Group A Streptococcus In Aboriginal Communities
Funder
National Health and Medical Research Council
Funding Amount
$856,896.00
Summary
Skin sores are highly prevalent in remote Australian Indigenous communities and can lead to invasive infections and rheumatic heart disease. We will develop mathematical models to understand the transmission of skin sores, allowing us to define the optimal extent (household, community, region), timing and triggers for interventions to interrupt transmission. This will guide public health policy in reducing the prevalence of skin sores and scabies, and their accompanying disease burden.
Zinc As An Antimicrobial Agent And Its Effect On The Pathogenesis Of Group A Streptococcus
Funder
National Health and Medical Research Council
Funding Amount
$352,359.00
Summary
This proposal focuses on Group A Streptococcus (GAS), a human pathogen estimated to cause 600,000 human deaths per year. We have shown that the host immune system uses zinc as an antibacterial agent and that GAS has processes that protect against zinc overload. We will determine the way in which zinc mobilization controls GAS infection and how GAS responds to to an increase in zinc concentration. The results will provide new insights into zinc’s role in protection against bacterial infections.